KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Astrazeneca (AZN) over the last 15 years, with Q4 2025 value amounting to -$652.0 million.

  • Astrazeneca's Gains from Investment Securities rose 1554.4% to -$652.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.8 billion, marking a year-over-year decrease of 345.45%. This contributed to the annual value of -$2.8 billion for FY2025, which is 345.45% down from last year.
  • Per Astrazeneca's latest filing, its Gains from Investment Securities stood at -$652.0 million for Q4 2025, which was up 1554.4% from -$644.0 million recorded in Q3 2025.
  • Astrazeneca's 5-year Gains from Investment Securities high stood at $1.2 billion for Q4 2021, and its period low was -$1.2 billion during Q2 2025.
  • For the 5-year period, Astrazeneca's Gains from Investment Securities averaged around -$479.1 million, with its median value being -$642.5 million (2024).
  • Per our database at Business Quant, Astrazeneca's Gains from Investment Securities skyrocketed by 9811.32% in 2021 and then crashed by 243333.33% in 2022.
  • Quarter analysis of 5 years shows Astrazeneca's Gains from Investment Securities stood at $1.2 billion in 2021, then plummeted by 165.16% to -$778.0 million in 2022, then fell by 7.46% to -$836.0 million in 2023, then increased by 7.66% to -$772.0 million in 2024, then rose by 15.54% to -$652.0 million in 2025.
  • Its Gains from Investment Securities was -$652.0 million in Q4 2025, compared to -$644.0 million in Q3 2025 and -$1.2 billion in Q2 2025.